Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 HPLC analysis of dopamine and its metabolites in G2019S LRRK2 transgenic mice. A–D, Levels of (A) dopamine (DA) and its metabolites, (B) DOPAC and (C) HVA, and (D) dopamine turnover ([DOPAC+HVA]/DA) in the striatum, olfactory bulb and cerebral cortex of 14–15 month-old G2019S LRRK2 TG mice (line 340) and their NTG littermates by HPLC analysis (n = 8/genotype). Bars present the mean ± SEM. *P<0.05 or **P<0.005 comparing TG with NTG as indicated.](https://figures.cochat.ai/paper-figures/2d21c616818941c89c421afafe071ad7/dopaminergic-neuronal-loss-reduced-neurite-complexity-and-autophagic-figure-4.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dysregulated autophagy has also been associated with the expression of dominant mutants of LRRK2 (leucine‐rich repeat kinase 2) (Ramonet et al, 2011), the most common cause of familial PD.”
From Autophagy in major human diseases (2021) · cites this paper as Ramonet et al, 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 2×
“LRRK2-linked PD is characterized by the degeneration of substantia nigra dopaminergic neurons and gliosis together with heterogeneous protein inclusion pathology [3,10].”
BackgroundCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. V., Rudka, T., Bartoli, D., Polishuck, R. S., Danial, N. N., De Strooper, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.025 · Cited by 1,673 · cited 1×
“area was determined for LRRK2 transgenic (TG) and non-transgenic (NTG) mice. Mitochondria were subclassified as either morphologically normal (class I), damaged (class II) or abnormally condensed/aggregated based upon previously established criteria (”
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425 · cited 1×
“-linked families, including the R1441C/G/H, Y1699C, G2019S and I2020T variants”
BackgroundParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“1-LRRK2-Myc-His vector [18] was previously modified to introduce a 59 Kozak sequence and 39 stop codon (TAA) between flanking NheI sites.”
Self-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“Unbiased stereological methodology was employed as described previously [55,56] to count TH+ and Nissl+ neurons in the left and right pars compacta region of every fourth section throughout the ventral midbrain.”
MethodA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774 · cited 1×
“. Of these, G2019S is the most common variant that uniquely contributes to both familial and sporadic PD”
BackgroundKinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671 · cited 1×
“LRRK2-induced neuronal toxicity in vitro in a GTP-binding- and kinase-dependent manner [13,19-22], suggesting a gain-of-function mechanism for familial mutations.”
BackgroundLRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055509 · Cited by 665
Cited by
Items 101–200 of 406
Sloan, M., Alegre-Abarrategui, J., Potgieter, D., Kaufmann, A.-K., Exley, R., Deltheil, T., Threlfell, S., Connor-Robson, N., Brimblecombe, K., Wallings, R., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv628 · Cited by 73
Non-Motor and Motor Features in LRRK2 Transgenic Mice
Bichler, Z., Lim, H. C., Zeng, L., & Tan, E. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070249 · Cited by 72
“models for PD have been developed, but most of them focus on motor and neuropathological features and they do not recapitulate entirely clinical PD [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32].”
BackgroundParkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting
Williams, E. T., Glauser, L., Tsika, E., Jiang, H., Islam, S., & Moore, D. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy224 · Cited by 72
Self-citationTargeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease
Rivero-Ríos, P., Madero-Pérez, Fernández, B., & Hilfiker, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030103027 · Cited by 69
“Whilst knockdown or kinase inhibition seem to cause increased autophagic flux [27, 28], pathogenic mutant LRRK2 elicits phenotypes consistent with a block in autophagy, leading to accumulation of undegraded material, lysosome-like structures and lipid droplets in cell as well as animal model systems [29-38].”
Podhajska, A., Musso, A., Trancikova, A., Stafa, K., Moser, R., Sonnay, S., Glauser, L., & Moore, D. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039942 · Cited by 67
“Immunocytochemistry and confocal microscopy Immunocytochemical staining was conducted as previously described [36].”
MethodSelf-citationMechanisms of LRRK2-Mediated Neurodegeneration
Tsika, E., & Moore, D. J. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0265-8 · Cited by 74
Self-citationProtective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity
Nixon-Abell, J., Berwick, D. C., Grannó, S., Spain, V. A., Blackstone, C., & Harvey, K. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00018 · Cited by 69
“Recently, a number of genetic screens have reported an inherited R1398H LRRK2 variant in the Roc domain (Chen et al., 2010; Tan et al., 2010; Ross et al., 2011; Heckman et al., 2013, 2014) that appears to confer decreased risk of PD.”
BackgroundTrafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s disease
Iovino, L., Giusti, V., Pischedda, F., Giusto, E., Plotegher, N., Marte, A., Battisti, I., Di Iacovo, A., Marku, A., Piccoli, G., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02437-0 · Cited by 60
“According with previous reports [39, 69, 106], Tyrosine Hydroxylase (TH) levels as quantified by western blot from the same mice revealed no signs of”
ResultSu, Y.-C., Guo, X., & Qi, X. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.009 · Cited by 64
“Several recent lines of evidence have shown that the LRRK2 G2019S mutant causes mitochondrial dysfunction and aberrant autophagy in fibroblasts from PD patients with the mutation [12–16], in dopaminergic neurons derived from induced pluripotent stem cells of PD patients [17], and in transgenic mice in which a human LR…”
Matikainen-Ankney, B. A., Kezunovic, N., Menard, C., Flanigan, M. E., Zhong, Y., Russo, S. J., Benson, D. L., & Huntley, G. W. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1457-18.2018 · Cited by 69
“The neurobiology underlying any such transition is unknown, but may involve progressive G2019S-driven pathological changes to dopamine (Ramonet et al., 2011; Yue et al., 2015; Pan et al., 2017; Volta et al., 2017; Xiong et al., 2018), serotonin (Lim et al., 2018), or other systems colluding with…”
BackgroundRudenko, I. N., Chia, R., & Cookson, M. R. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-20 · Cited by 63
“In cultured neurons, neurite shortening is also a rather consistent phenotype associated with mutant LRRK2, even in models where cell death is not apparent [28,53-58].”
BackgroundKorecka, J. A., Thomas, R., Christensen, D. P., Hinrich, A. J., Ferrari, E. J., Levy, S. A., Hastings, M. L., Hallett, P. J., & Isacson, O. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz126 · Cited by 64
“tion of damaged mitochondria is observed in G2019S transgenic mice (31).”
BackgroundVolta, M., & Melrose, H. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160238 · Cited by 64
Viral Vector-Based Models of Parkinson’s Disease
der Perren, A. V., den Haute, C. V., & Baekelandt, V. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_310 · Cited by 80
“2009), or the G2019S mutation in LRRK2 (Ramonet et al. 2011).”
BackgroundBack and to the Future: From Neurotoxin‐Induced to Human Parkinson's Disease Models
Airavaara, M., Parkkinen, I., Konovalova, J., Albert, K., Chmielarz, P., & Domanskyi, A. (2020) · Current Protocols in Neuroscience · doi:10.1002/cpns.88 · Cited by 66
“Several transgenic mouse lines have been created carrying PD-associated mutations in LRRK2, but none recapitulate the Parkinsonian phenotype observed in human patients (Bichler, Lim, Zeng, & Tan, 2013; Chen et al., 2012; Li et al., 2010; Li et al., 2009; Ramonet et al., 2011; Weng et al., 2016).”
BackgroundDodson, M. W., Leung, L. K., Lone, M., Lizzio, M. A., & Guo, M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.017020 · Cited by 59
“…forms of LRRK2 result in the accumulation of aberrant lysosomal and autophagosomal structures (Alegre-Abarrategui et al., 2009; BravoSan Pedro et al., 2012; Gómez-Suaga et al., 2012; MacLeod et al., 2006; MacLeod et al., 2013; Orenstein et al., 2013; Plowey et al., 2008; Ramonet et al., 2011).”
BackgroundThe LRRK2–macroautophagy axis and its relevance to Parkinson's disease
Manzoni, C. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160265 · Cited by 60
Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity
Nguyen, A. P. T., & Moore, D. J. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_4 · Cited by 59
Self-citationDeregulation of autophagy and vesicle trafficking in Parkinson’s disease
Sheehan, P., & Yue, Z. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.013 · Cited by 71
“Interestingly, mouse models harboring LRRK2 hyperactive kinase mutations display defects in synaptic and autophagic function, suggesting chronic phosphorylation of Rab GTPases may underlie these alterations [36, 42, 43].”
BackgroundToyofuku, T., Morimoto, K., Sasawatari, S., & Kumanogoh, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00085-15 · Cited by 57
“In contrast to the role of LRRK1 in autophagosome biogenesis, deletion or pathogenic mutation of LRRK2 causes a defect in autophagosome maturation, as revealed by the reduced conversion of LC3-I to LC3-II during autophagy (16, 18, 19).”
BackgroundManzoni, C., & Lewis, P. A. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-49969-7_5 · Cited by 60
Liu, G., Sgobio, C., Gu, X., Sun, L., Lin, X. Z., Yu, J. H., Parisiadou, L., Xie, C., Sastry, N. G., Ding, J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv249 · Cited by 67
“However, although one model of LRRK2 G2019S transgenic mice developed significant (∼17%) neuron loss (37), in the major-”
BackgroundLongo, F., Russo, I., Shimshek, D. R., Greggio, E., & Morari, M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.013 · Cited by 57
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s disease
Tozzi, A., Tantucci, M., Marchi, S., Mazzocchetti, P., Morari, M., Pinton, P., Mancini, A., & Calabresi, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0221-2 · Cited by 54
Contribution of GTPase activity toLRRK2-associated Parkinson disease
Tsika, E., & Moore, D. J. (2013) · Small GTPases · doi:10.4161/sgtp.25130 · Cited by 59
Self-citationRudenko, I. N., & Cookson, M. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0284-z · Cited by 61
“Two transgenic mouse models overexpressing human G2019S LRRK2 exhibit modest age-dependent DA neuron loss associated with accumulation of autophagosomes and mitochondrial alterations [124, 125], but other G2019S LRRK2 transgenic mouse models had diminished dopamine transmission and motor deficits without detectable ne…”
BackgroundLin, C.-H., Lin, H.-I., Chen, M.-L., Lai, T.-T., Cao, L.-P., Farrer, M. J., Wu, R.-M., & Chien, C.-T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw068 · Cited by 55
“Those reports indicated that abnormal neurite morphology, namely a reduction in neurite length and complexity, was a disease-related phenotype of LRRK2 parkinsonism (15,16).”
BackgroundLRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Atashrazm, F., & Dzamko, N. (2016) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s102191 · Cited by 53
“Early studies in cells, 26,27 flies, 28 worms, 29,30 and transgenic animal models 31–33 demonstrated that overexpression of G2019S LRRK2 could induce or potentiate PD-like neuro-degenerative phenotypes, particularly in regard to neuronal toxicity, dopamine transmission, and neurite morphology.”
Karuppagounder, S. S., Xiong, Y., Lee, Y., Lawless, M. C., Kim, D., Nordquist, E., Martin, I., Ge, P., Brahmachari, S., Jhaldiyal, A., et al. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.01.007 · Cited by 57
“Although, LRRK2 G2019S expression in this model was relatively modest, it was sufficient to induce age dependent DA neurodegeneration (Ramonet et al., 2011).”
BackgroundMethodInfluentialSelf-citationTakanashi, M., Funayama, M., Matsuura, E., Yoshino, H., Li, Y., Tsuyama, S., Takashima, H., Nishioka, K., & Hattori, N. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0617-y · Cited by 57
Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models
Kramer, T., Lo Monte, F., Göring, S., Okala Amombo, G. M., & Schmidt, B. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200117j · Cited by 52
LRRK2 impairs autophagy by mediating phosphorylation of leucyl‐tRNA synthetase
Ho, D. H., Kim, H., Nam, D., Sim, H., Kim, J., Kim, H., Son, I., & Seol, W. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3364 · Cited by 55
Self-citationProgress in LRRK2-Associated Parkinson’s Disease Animal Models
Seegobin, S. P., Heaton, G. R., Liang, D., Choi, I., Ramírez, M. B., Tang, B., & Yue, Z. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00674 · Cited by 62
“15 Ramonet et al., 2011 Human LRRK2 R1441C.”
BackgroundInfluentialMachine learning discriminates a movement disorder in a zebrafish model of Parkinson's disease
Hughes, G. L., Lones, M. A., Bedder, M., Currie, P. D., Smith, S. L., & Pownall, M. E. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045815 · Cited by 60
“In contrast, transgenic expression of genes associated with autosomal dominant PD in humans, LRRK2 (G2019S) and SNCA , was shown to cause a loss of nigrostriatal DA neurons and locomotor defects in the mouse (Ramonet et al., 2011; Janezic et al., 2013).”
BackgroundBell, R., & Vendruscolo, M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.661117 · Cited by 55
Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
Liu, H., Ho, P. W., Leung, G. C.-T., Lam, C. S.-C., Pang, S. Y.-Y., Li, L., Kung, M. H.-W., Ramsden, D. B., & Ho, S. (2017) · Scientific Reports · doi:10.1038/srep40887 · Cited by 59
Autophagy and LRRK2 in the Aging Brain
Albanese, F., Novello, S., & Morari, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01352 · Cited by 55
“Furthermore, in most cases, neurodegenerative diseases are associated with the inheritance of mutations in genes controlling the autophagic process, suggesting that aberrant autophagy might contribute to neurodegeneration (Ravikumar et al., 2002; Berger et al., 2006; Ravikumar et al., 2006).”
BackgroundRay, S. S., & Liu, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.110 · Cited by 56
Lim, J., Bang, Y., Choi, J.-H., Han, A., Kwon, M., Liu, K., & Choi, H. J. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.4051-15.2017 · Cited by 50
“Although all these regions strongly express LRRK2 (Taymans et al., 2006; Ramonet et al., 2011), a significant decrease in 5-HT was observed only in the hippocampus.”
BackgroundMethodInfluentialSanyal, A., Novis, H. S., Gasser, E., Lin, S. C., & LaVoie, M. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00442 · Cited by 53
Giovedì, S., Ravanelli, M. M., Parisi, B., Bettegazzi, B., & Guarnieri, F. C. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.602116 · Cited by 56
“Idiopathic PD brains and transgenic mice carrying LRRK2 mutations exhibit autophagic, endolysosomal and mitochondrial abnormalities (Ramonet et al., 2011; Rocha et al., 2020).”
BackgroundThe unlikely partnership between LRRK 2 and α‐synuclein in Parkinson's disease
Cresto, N., Gardier, C., Gubinelli, F., Gaillard, M., Liot, G., West Andrew, B., & Brouillet, E. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14182 · Cited by 54
“, 2002), when crossed with G2019SLRRK2 mice expressing mutant LRRK2 under the control of the CMVe- PDGFb promoter, demonstrated mild enhancement of phosphorylated inclusions but did not worsen survival rates or other phenotypes (Daher et al., 2012; Ramonet et al., 2011).”
BackgroundTsika, E., Nguyen, A. P. T., Dusonchet, J., Colin, P., Schneider, B. L., & Moore, D. J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.019 · Cited by 46
Self-citationShort- and Long-Term Effects of LRRK2 on Axon and Dendrite Growth
Sepulveda, B., Mesias, R., Li, X., Yue, Z., & Benson, D. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061986 · Cited by 47
“Population studies of fixed neurons grown on laminin carried out over the course of three weeks of development reveal a sustained, negative effect of LRRK2-G2019S on dendritic growth and arborization, a finding consistent with previous work [12,24].”
BackgroundResultInfluentialMitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease
Podlesniy, P., Vilas, D., Taylor, P., Shaw, L. M., Tolosa, E., & Trullas, R. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.019 · Cited by 43
“Actually, studies in cultured neurons, neuroblastoma cells and transgenic mice have shown that the LRRK2 G2019S mutation disrupts mitochondrial dynamics and enhances mitophagy (Wang et al., 2012;Niu et al., 2012;Su & Qi, 2013;Cherra, III et al., 2013;Ramonet et al., 2011).”
Adeosun, S. O., Hou, X., Zheng, B., Stockmeier, C., Ou, X., Paul, I., Mosley, T., Weisgraber, K., & Wang, J. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497909 · Cited by 44
“We compared the alternation percentage of each genotype (Arg-61 and C57Bl/6J) to 50% chance level using the one-sample t test (25).”
MethodDrolet, R. E., Sanders, J. M., & Kern, J. T. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.627072 · Cited by 44
Palomo‐Garo, C., Gómez‐Gálvez, Y., García, C., & Fernández‐Ruíz, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.04.004 · Cited by 47
G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain
Nguyen, A. P. T., Daniel, G., Valdés, P., Islam, M. S., Schneider, B. L., & Moore, D. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx389 · Cited by 45
“G2019S LRRK2 is broadly expressed throughout the brain of PDGFb-LRRK2 transgenic mice with highest expression in the olfactory bulb, cerebral cortex, hippocampus, striatum and cerebellum (35).”
BackgroundInfluentialSelf-citationFrom cell lines to pluripotent stem cells for modelling Parkinson's Disease
Ferrari, E. S., Cardinale, A., Picconi, B., & Gardoni, F. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108741 · Cited by 47
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease
Chang, E. E. S., Ho, P. W., Liu, H., Pang, S. Y.-Y., Leung, C.-T., Malki, Y., Choi, Z. Y.-K., Ramsden, D. B., & Ho, S. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00285-2 · Cited by 52
Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration
Plowey, E. D., Johnson, J. W., Steer, E., Zhu, W., Eisenberg, D. A., Valentino, N. M., Liu, Y.-J., & Chu, C. T. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.016 · Cited by 41
Self-citationMaekawa, T., Mori, S., Sasaki, Y., Miyajima, T., Azuma, S., Ohta, E., & Obata, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-15 · Cited by 41
“expressing the G2019S mutation in the LRRK2 kinase domain, have been reported [12-15].”
BackgroundGenetically engineered animal models of Parkinson's disease: From worm to rodent
Breger, L. S., & Armentero, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14300 · Cited by 47
“Contradictory data, showing either absence or presence of neurodegeneration, have been obtained when human mutant (G2019S) LRRK2 protein is expressed under the control of the CMVE- PDGF- β promoter (Chen et al., 2012; Ramonet et al., 2011).”
BackgroundG2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice
Arbez, N., He, X., Huang, Y., Ren, M., Liang, Y., Nucifora, F. C., Wang, X., Pei, Z., Tessarollo, L., Smith, W. W., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz271 · Cited by 44
“dopaminergic neuronal loss even in late life stages (24,43).”
BackgroundAn early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease
Tagliaferro, P., Kareva, T., Oo, T. F., Yarygina, O., Kholodilov, N., & Burke, R. E. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.009 · Cited by 43
LRRK 2 R1441G mice are more liable to dopamine depletion and locomotor inactivity
Liu, H., Lu, S., Ho, P. W., Tse, H., Pang, S. Y., Kung, M. H., Ho, J. W., Ramsden, D. B., Zhou, Z., & Ho, S. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.45 · Cited by 44
Trancikova, A., Mamais, A., Webber, P. J., Stafa, K., Tsika, E., Glauser, L., West, A. B., Bandopadhyay, R., & Moore, D. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047784 · Cited by 43
“In this context, one could speculate that LRRK2-dependent 4E-BP1 phosphorylation may occur in aging flies due to inherent stress, as reflected by the increased sensitivity of dLRRK transgenic flies exposed to oxidative insult [25], whereas the LRRK2 knockout and transgenic mice at the ages used in this study do not de…”
BackgroundSelf-citationULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression
Zhu, Y., Wang, C., Yu, M., Cui, J., Liu, L., & Xu, Z. (2013) · Protein & Cell · doi:10.1007/s13238-013-3910-3 · Cited by 46
Nikonova, E. V., Xiong, Y., Tanis, K. Q., Dawson, V. L., Vogel, R. L., Finney, E. M., Stone, D. J., Reynolds, I. J., Kern, J. T., & Dawson, T. M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr451 · Cited by 41
“LRRK2 transgenic (G2019S) mice overexpress LRRK2 under the direction of a CMVe-PDGF-b promoter as described previously (38,50).”
BackgroundMethodInfluentialSelf-citationLRRK2 mutations and neurotoxicant susceptibility
Lee, J.-W., & Cannon, J. R. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215579162 · Cited by 44
“In contrast, under the control of CMV-enhanced human platelet-derived growth factor b-chain (CMVEPDGFb) promoter, human G2019S LRRK2 overexpression did induce nigrostriatal DA neurodegeneration (stereological counts in SN pars compacta and stereological measurements of neurite density in SN pars reticulata) in an aged…”
BackgroundDaniel, G., Musso, A., Tsika, E., Fiser, A., Glauser, L., Pletnikova, O., Schneider, B. L., & Moore, D. J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.007 · Cited by 39
Self-citationEsteves, A. R., & Cardoso, S. M. (2016) · The Neuroscientist · doi:10.1177/1073858415616558 · Cited by 43
Chen, M., & Wu, R. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0454-0 · Cited by 43
“An investigation of the regulation of the tissue specificity of LRRK2 expression by autophagy showed the age-dependent accumulation of autophagic vacuoles in the cortex and striatum of R1441C and G2019S transgenic mice, suggesting that LRRK2 expression is only regulated by autophagy in neuronal somas and axial process…”
BackgroundComprehensive Perspectives on Experimental Models for Parkinson’s Disease
Ke, M., Chong, C., Zhu, Q., Zhang, K., Cai, C.-Z., Lu, J., Qin, D., & Su, H. (2021) · Aging and Disease · doi:10.14336/ad.2020.0331 · Cited by 44
“Several transgenic techniques have been applied to establish pathological models of LRRK2 in rodents, including tetracycline transactivator–controlled inducible transgenic [214], CMVE/PDGF transgenic [215], Thy1 transgenic [216], BAC transgenic [217-221], and knockin techniques [222, 223].”
MethodXiong, Y., Neifert, S., Karuppagounder, S. S., Stankowski, J. N., Lee, B. D., Grima, J. C., Chen, G., Ko, H. S., Lee, Y., Swing, D., et al. (2017) · eneuro · doi:10.1523/eneuro.0004-17.2017 · Cited by 41
Self-citationMechanisms of Mutant LRRK2 Neurodegeneration
Cookson, M. R. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-49969-7_12 · Cited by 43
Therapeutic strategies in Parkinson's disease: what we have learned from animal models
Valadas, J. S., Vos, M. H., & Verstreken, P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12577 · Cited by 45
Price, A., Manzoni, C., Cookson, M. R., & Lewis, P. A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2759-9 · Cited by 39
“A number of these studies have focused on the expression of G2019S LRRK2 and indicate that this mutation promotes an increase of autophagic vacuoles and other autophagic abnormalities in both SH-SY5Y cells (Plowey et al. 2008) and transgenic mice (Ramonet et al. 2011).”
Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease
Kang, J., Kim, J. W., Heo, H., Lee, J., Park, K. Y., Yoon, J. H., & Chang, J. (2020) · Clinical and Translational Science · doi:10.1111/cts.12920 · Cited by 40
“12 In addition, LRRK2 and DJ-1 are reported to play important roles in autophagy-mediated DA neuronal cell loss.(13,14) Most recently, Laperle et al.”
BackgroundSelf-citationRole of LRRK2 kinase activity in the pathogenesis of Parkinson's disease
Greggio, E. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120054 · Cited by 38
Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson’s Disease
Johnson, W. M., Golczak, M., Choe, K., Curran, P. L., Miller, O. G., Yao, C., Wang, W., Lin, J., Milkovic, N. M., Ray, A., et al. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01132 · Cited by 43
Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Sidorova, Y. A., Volcho, K. P., & Salakhutdinov, N. F. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180905094123 · Cited by 40
ERKed by LRRK2: A cell biological perspective on hereditary and sporadic Parkinson's disease
Verma, M., Steer, E. K., & Chu, C. T. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.11.005 · Cited by 36
Leucine-Rich Repeat Kinase 2 for Beginners: Six Key Questions
Kett, L. R., & Dauer, W. T. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009407 · Cited by 43
“Lastly, as noted above, LRRK2 loss-of-function and overexpression of PDmutant LRRK2 have opposite effects on neurite outgrowth (MacLeod et al. 2006; Parisiadou et al. 2009; Dachsel et al. 2010; Lin et al. 2010; Ramonet et al. 2011).”
BackgroundVitamin D receptor genetic variants and Parkinson's disease in a Taiwanese population
Lin, C.-H., Chen, K.-H. S., Chen, M., Lin, H.-I., & Wu, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.094 · Cited by 37
The role of LRRK2 in cytoskeletal dynamics
Civiero, L., Cogo, S., Biosa, A., & Greggio, E. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180469 · Cited by 36
LRRK2 interferes with aggresome formation for autophagic clearance
Bang, Y., Kim, K., Seol, W., & Choi, H. J. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.06.007 · Cited by 42
iPS cells in the study of PD molecular pathogenesis
Cobb, M. M., Ravisankar, A., Skibinski, G., & Finkbeiner, S. M. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2749-y · Cited by 37
“…or other pathogenic LRRK2 mutations occur in multiple models, including rodent neurons and neuroblastoma cell lines (MacLeod et al. 2006; Plowey et al. 2008; Ramonet et al. 2011; Winner et al. 2011) and dystrophic Lewy neurites and axonal degeneration are found in PD (Bellucci et al. 2016).”
BackgroundKuhlmann, N., & Milnerwood, A. J. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00153 · Cited by 38
“…et al., 2012; Liu et al., 2015), cytoskeletal changes (Parisiadou et al., 2009; Winner et al., 2011), synaptic plasticity deficits (Sweet et al., 2015), phosphorylated tau accumulation (Melrose et al., 2010; Chen et al., 2012) andmitochondrial dysfunction (Ramonet et al., 2011; Liu et al., 2015).”
BackgroundSanna, G., Giudice, M. G. D., Crosio, C., & Iaccarino, C. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120117 · Cited by 41
Mouse models for LRRK2 Parkinson's disease
Xu, Q., Shenoy, S. A., & Li, C. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70058-x · Cited by 39
“Higher levels of transgene expression are correlated with stronger PD-like phenotypes [20,22].”
BackgroundThe LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation
Bae, E.-J., & Lee, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165632 · Cited by 36
Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders
Newland, B., Newland, H., Werner, C., Rosser, A., & Wang, W. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.12.002 · Cited by 38
68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment
Thomas, J. M., Li, T., Yang, W., Xue, F., Fishman, P. S., & Smith, W. W. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00337 · Cited by 37
“LRRK2 has been shown to regulate neuronal outgrowth and intracellular events necessary for maintaining healthy neurons (Ramonet et al., 2011; Su and Qi, 2013).”
BackgroundTang, X., Xing, S., Ma, M., Xu, Z., Guan, Q., Chen, Y., Feng, F., Liu, W., Chen, T., Chen, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01552 · Cited by 30
A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling
Gómez‐Suaga, P., Churchill, G. C., Patel, S., & Hilfiker, S. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120138 · Cited by 37
Braithwaite, S. P., Voronkov, M. V., Stock, J. B., & Mouradian, M. M. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.01.031 · Cited by 35
LRRK2: an éminence grise of Wnt-mediated neurogenesis?
Berwick, D. C., & Harvey, K. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00082 · Cited by 43
Autophagy and lysosomal pathways in nervous system disorders
Bingol, B. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.04.009 · Cited by 35
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
Pischedda, F., Cirnaru, M., Ponzoni, L., Sandre, M., Biosa, A., Pérez‐Carrión, M. D., Marin, O., Morari, M., Pan, L., Greggio, E., et al. (2021) · Brain · doi:10.1093/brain/awab073 · Cited by 35
Xenias, H. S., Chen, C., Kang, S., Cherian, S., Situ, X., Shanmugasundaram, B., Liu, G., Scesa, G., Chan, C. S., & Parisiadou, L. (2022) · Communications Biology · doi:10.1038/s42003-022-04136-8 · Cited by 32
A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease
Gómez‐Suaga, P., Fdez, E., Ramírez, M. B., & Hilfiker, S. (2012) · Parkinson s Disease · doi:10.1155/2012/324521 · Cited by 30
“Similarly, an accumulation of autophagic vacuoles, including early and late autophagosomes, has been described in the soma and processes in the cortex and striatum from G2019S, and to a lesser degree R1441C, transgenic mice with advanced age [40].”
BackgroundInteraction of LRRK2 and α-Synuclein in Parkinson’s Disease
Daher, J. P. L. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-49969-7_11 · Cited by 33
Self-citationNovel models for Parkinson’s disease and their impact on future drug discovery
Trigo‐Damas, I., del Rey, N. L., & Blesa, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1428556 · Cited by 34
“On the other side, overexpression of any of the mutations in rat or mice models causes none or a mild loss of dopaminergic neurons of the SNc, with no alterations again in the DA levels of the striatum or locomotor activity [47,48].”
BackgroundExogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate.
Mestre-Francés, N., Serratrice, N., Gennetier, A., Devau, G., Cobo, S., Trouche, S. G., Fontés, P., Zussy, C., Deurwaerdère, P. D., Salinas, S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98202 · Cited by 23
“Our results are consistent with reports describing the association of fragmented axons with axonal spheroids and dystrophic neurites in LRRK2R1441G-transgenic mice (45) and other pathological changes in cell body and axons of transgenic mice overexpressing LRRK2G2019S (46).”
ResultLamonaca, G., & Volta, M. (2020) · Cells · doi:10.3390/cells9051115 · Cited by 32
“For example, primary mouse cortical neurons expressing G2019S-LRRK2 demonstrated increased mitophagy associated with altered Ca2+ levels [66], and ultrastructure examination in G2019S-LRRK2 transgenic mice showed an accumulation of damaged mitochondria, consistent with altered mitophagy in aged mice [67].”
BackgroundLRRK2 at the Crossroad of Aging and Parkinson’s Disease
Hur, E., & Lee, B. D. (2021) · Genes · doi:10.3390/genes12040505 · Cited by 33
Weng, Y.-H., Chen, C., Lin, K.-J., Chen, Y., Yeh, T., Hsiao, I., Chen, I.-J., Lu, C.-S., & Wang, H. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.001 · Cited by 34
Garcia‐Miralles, M., Coomaraswamy, J., Häbig, K., Herzig, M. C., Funk, N., Gillardon, F., Maisel, M., Jucker, M., Gasser, T., Galter, D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118947 · Cited by 31
Self-citation
Metadata
- Authors
- Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., & Moore, D. J.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Johns Hopkins University (US)
- University of Minnesota (US)
- Cornell University (US)
- Karolinska Institutet (SE)
- National Cancer Institute (US)
- Corresponding author
- Dawson, Valina L.
- Moore, Darren J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-06
- Volume
- 6
- Issue
- 4
- Pages
- e18568
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3071839
- OpenAlex
- W2166593844
- Cited by
- 405
- References
- 61
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 23 · 2021: 27 · 2020: 31 · 2019: 28 · 2018: 33 · 2017: 32 · 2016: 27 · 2015: 27 · 2014: 39 · 2013: 36 · 2012: 44
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Science Foundation
- National Parkinson Foundation
- American Parkinson Disease Association
- Johns Hopkins University
- École Polytechnique Fédérale de Lausanne
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (127478)
- Vetenskapsrådet
- Parkinson Schweiz
- National Institutes of Health
- Parkinsonfonden
- National Institute of Neurological Disorders and Stroke (R01NS060885, NS060885, NS03877, P50NS038377, NS062165, R21NS062165)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- LRRK2, G2019S mutation, familial Parkinson's disease, transgenic mouse model, dopaminergic neuron loss, nigrostriatal pathway, neurite complexity, autophagy, mitochondrial abnormalities, age-related neurodegeneration
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Animals, Autophagy, Behavior, Animal, Chromatography, High Pressure Liquid, Dopamine, Humans, Mesencephalon, Mice, Transgenic, Motor Activity, Organ Culture Techniques, Neurites, Protein Serine-Threonine Kinases, Amino Acid Substitution, Protein Transport, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.